Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia.
We studied the effects of CAS1609, a nitric oxide donor, on leukocyte-endothelial interactions during the early stages of hypercholesterolemia in rat mesenteric microcirculation. Rats were randomly divided into four groups: (a) rats fed control diet, (b) rats fed control diet while receiving CAS1609, (c) rats fed a high-cholesterol (HC) diet and given C93-4845 (an inactive control compound), and (d) rats fed an HC diet and given CAS1609. Both HC groups developed significantly elevated plasma cholesterol levels compared with rats fed the control diet. Intravital microscopy of mesenteric venules revealed a significant increase in leukocyte rolling and adherence in the untreated HC rats compared with control rats (P < .01). This was significantly attenuated in the HC rats given CAS1609. The HC rats given C93-4845 also developed aortic endothelial dysfunction (ie, impaired relaxation to acetylcholine or ADP) that was significantly prevented by CAS1609 infusion (P < .02). Immunohistochemical staining of ileum demonstrated significantly enhanced localization of P-selectin and intercellular adhesion molecule-1 (ICAM-1) on venular endothelium in the untreated HC rats compared with control rats (P < .01). However, P-selectin and ICAM-1 expression were significantly attenuated in HC rats given CAS1609 (P < .05 and P < .01, respectively). Thus, hypercholesterolemia induces microvascular dysfunction characterized by loss of endothelium-derived nitric oxide, increased rolling and adherence of leukocytes, and increased expression of P-selectin and ICAM-1. Infusion of CAS1609 significantly attenuated these changes due to hypercholesterolemia. Our data suggest that nitric oxide plays a significant role in the prevention of the early endothelial dysfunction observed in hypercholesterolemia.
Gauthier
T W
TW
Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Scalia
R
R
Murohara
T
T
Guo
J P
JP
Lefer
A M
AM
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects*; D002791:Cholesterol, Dietary; D004730:Endothelium, Vascular / Q000473:pathology; D006937:Hypercholesterolemia / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology*; D007082:Ileum / Q000098:blood supply; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis; D007962:Leukocytes / Q000473:pathology; D008297:Male; D008833:Microcirculation / Q000378:metabolism / Q000503:physiopathology*; D009569:Nitric Oxide / Q000494:pharmacology / Q000502:physiology*; D010069:Oxadiazoles / Q000494:pharmacology*; D019007:P-Selectin / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D014665:Vasodilator Agents / Q000494:pharmacology*
C094475:4-hydroxynethyl-furoxan-3-carboxamide; D002791:Cholesterol, Dietary; D010069:Oxadiazoles; D019007:P-Selectin; D014665:Vasodilator Agents; D018799:Intercellular Adhesion Molecule-1; D009569:Nitric Oxide